<DOC>
	<DOCNO>NCT00397189</DOCNO>
	<brief_summary>This randomise , placebo control study evaluate efficacy 3 week treatment period Circadin® 2 mg shorten sleep latency patient primary insomnia age 18-80 melatonin deficiency .</brief_summary>
	<brief_title>Efficacy Safety Circadin® 2 mg Treatment Primary Insomnia Patients</brief_title>
	<detailed_description>Studies throughout world show insomnia common complaint occur 10-50 % population depend age , sex country . Among wide variety available treatment sleep disturbance , commonly prescribe hypnotic benzodiazepine ( BZD ) non-BZD hypnotic . However , hypnotic often associate rebound , dependency , tolerance , high risk fall mainly elderly population , anterograde memory disturbance increase risk motor accident next day . In response unmet clinical need safe efficacious alternative treatment primary insomnia , addition treat quantitative sleep problem , would improve sleep quality daytime functioning , clinical development program melatonin treatment primary insomnia initiate . This study conduct use randomise , double-blind , placebo control parallel group design , single-blind placebo period . Primary insomnia patient age 18-80 screened entry study . After initial 3 week double-blind treatment period , patient give option enter six-month double-blind continuation study . Primary parameter sleep latency , secondary parameter sleep maintenance . Exploratory parameter total sleep time , sleep quality , morning alertness quality life .</detailed_description>
	<mesh_term>Sleep Initiation Maintenance Disorders</mesh_term>
	<mesh_term>Melatonin</mesh_term>
	<criteria>Male female age 1880 year . Are willing take 6SMT level evaluation test . Suffering primary insomnia accord DSMIV . criterion ( 307.42 primary insomnia , Appendix 24.3 ) . Sleep latency least 20 minute . Have use benzodiazepine ( BZD ) nonBZD hypnotic past 2 week . Have use psychotropic treatment past 3 month . Are stabilized nonpsychotropic treatment 1 month . Are willing sign write informed consent participate study . Use benzodiazepines hypnotic ( include psychotropic treatment ) study precede two week . Alcohol intake 30 g pure alcohol per day intake lunchtime . Pharmacological immunosuppression . Participation clinical trial investigational agent within two month prior study enrollment . According DSM IV , subject belong follow group exclude : 780.59 ( breathe relate sleep disorder ) ; 307.45 ( circadian rhythm sleep disorder ) ; 307.47 ( dyssomnia otherwise specify ) ; 780.xx ( sleep disorder due general medical condition ) . Severe neurological , psychiatric disorder ( especially psychosis , anxiety depression ) alcoholism . Other serious disease could interfere patient assessment . Pregnant breast feed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Primary insomnia define DSM IV criterion</keyword>
</DOC>